Published in Virology on April 15, 1980
Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol (1984) 5.89
Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol (1984) 4.98
Latent infection of KB cells with adeno-associated virus type 2. J Virol (1986) 2.88
DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J (2001) 2.43
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J Virol (1995) 1.86
A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol (2005) 1.79
A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A (2010) 1.78
Design and packaging of adeno-associated virus gene targeting vectors. J Virol (2000) 1.54
Adeno-associated virus rep protein synthesis during productive infection. J Virol (1989) 1.54
Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2. J Virol (1980) 1.54
Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol (1992) 1.52
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. Hum Gene Ther (2015) 1.27
The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol (2011) 1.23
In vitro packaging of adeno-associated virus DNA. J Virol (1998) 1.22
Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol (1999) 1.20
Properties of the adeno-associated virus assembly-activating protein. J Virol (2012) 1.06
Chromatin-like structure of adeno-associated virus DNA in infected cells. J Virol (1983) 1.03
Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J Virol (2006) 0.96
A cis-acting element that directs circular adeno-associated virus replication and packaging. J Virol (2002) 0.96
Structural insights into adeno-associated virus serotype 5. J Virol (2013) 0.92
Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther (2010) 0.91
Structure of a packaging-defective mutant of minute virus of mice indicates that the genome is packaged via a pore at a 5-fold axis. J Virol (2011) 0.89
A role for single-stranded templates in cell-free adeno-associated virus DNA replication. J Virol (2000) 0.87
cis effects in adeno-associated virus type 2 replication. J Virol (2007) 0.82
Substitution of adeno-associated virus Rep protein binding and nicking sites with human chromosome 19 sequences. Virol J (2010) 0.78
HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production. Gene Ther (2011) 0.78
Riboswitch-mediated Attenuation of Transgene Cytotoxicity Increases Adeno-associated Virus Vector Yields in HEK-293 Cells. Mol Ther (2015) 0.77
Symmetric-strand packaging of recombinant parvovirus LuIII genomes that retain only the terminal regions. J Virol (1995) 0.77
Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy. Hum Gene Ther (2014) 0.76
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet (1995) 7.55
Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol (1984) 4.98
Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene (1983) 4.15
Characteristics and taxonomy of Parvoviridae. Intervirology (1985) 3.70
Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A (1993) 3.59
Negative and positive regulation in trans of gene expression from adeno-associated virus vectors in mammalian cells by a viral rep gene product. Mol Cell Biol (1986) 3.34
Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. J Virol (1986) 3.09
Defective regulation of outwardly rectifying Cl- channels by protein kinase A corrected by insertion of CFTR. Nature (1992) 3.06
Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem (1993) 3.02
Spliced adenovirus-associated virus RNA. Proc Natl Acad Sci U S A (1979) 2.99
Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci U S A (1973) 2.96
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology (1989) 2.91
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
Calcium-channel blockers and risk of cancer. Lancet (1997) 2.53
Replication of adeno-associated virus DNA. Complementation of naturally occurring rep- mutants by a wild-type genome or an ori- mutant and correction of terminal palindrome deletions. J Mol Biol (1984) 2.51
Adeno-associated virus autointerference. Virology (1979) 2.43
In vivo model of adeno-associated virus vector persistence and rescue. J Virol (1996) 2.41
A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol (1984) 2.36
Adeno-associated virus vectors for gene therapy. Gene Ther (1995) 2.32
Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. J Virol (1993) 2.22
Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol (1985) 2.21
Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein. Proc Natl Acad Sci U S A (1981) 2.08
Defective-interfering particles of the human parvovirus adeno-associated virus. Virology (1979) 2.05
Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J Virol (1988) 2.03
Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells. J Biol Chem (1984) 1.99
Adenovirus-associated virus multiplication. IX. Extent of transcription of the viral genome in vivo. J Virol (1972) 1.87
Characterization of adeno-associated virus rep proteins in human cells by antibodies raised against rep expressed in Escherichia coli. Virology (1987) 1.85
Adeno-associated virus rep proteins produced in insect and mammalian expression systems: wild-type and dominant-negative mutant proteins bind to the viral replication origin. Virology (1991) 1.84
Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol (1992) 1.83
Adeno-associated virus RNA transcription in vivo. Eur J Biochem (1981) 1.83
Separate helper functions provided by adenovirus for adenovirus-associated virus multiplication. Nat New Biol (1973) 1.82
Regulation of adeno-associated virus gene expression in 293 cells: control of mRNA abundance and translation. J Virol (1988) 1.80
Effect of deletions in adenovirus early region 1 genes upon replication of adeno-associated virus. J Virol (1982) 1.76
Properties of an adenovirus type 2 mutant, Ad2dl807, having a deletion near the right-hand genome terminus: failure to help AAV replication. Virology (1983) 1.69
Adenovirus-associated virus multiplication. 8. Analysis of in vivo transcription induced by complete or partial helper viruses. J Virol (1972) 1.65
Replication of a human parvovirus nonsense mutant in mammalian cells containing an inducible amber suppressor. Virology (1989) 1.63
Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells. J Virol (1991) 1.59
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther (2001) 1.58
Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet (1996) 1.58
Transcription in vivo of a defective parvovirus: sedimentation and electrophoretic analysis of RNA synthesized by adenovirus-associated virus and its helper adenovirus. Virology (1974) 1.57
Mutation of a consensus purine nucleotide binding site in the adeno-associated virus rep gene generates a dominant negative phenotype for DNA replication. J Virol (1990) 1.56
Inhibition of cellular transformation by the adeno-associated virus rep gene. Virology (1991) 1.55
Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2. J Virol (1980) 1.54
Adeno-associated virus rep protein synthesis during productive infection. J Virol (1989) 1.54
Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures: lack of effect on intracellular viral markers. J Virol (1975) 1.49
Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J Virol (1994) 1.48
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope (1999) 1.47
Potentiation of human interferon production by superinduction. J Natl Cancer Inst (1971) 1.47
Specific cleavage of adenovirus-associated virus DNA by restriction endonuclease R-EcoRI--characterization of cleavage products. Virology (1975) 1.46
Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther (1996) 1.45
Genome localization of simian virus 40 RNA species. J Virol (1976) 1.41
Genome localization of adeno-associated virus RNA. J Virol (1976) 1.36
In vitro resolution of adeno-associated virus DNA hairpin termini by wild-type Rep protein is inhibited by a dominant-negative mutant of rep. J Virol (1992) 1.36
Gene expression in adeno-associated virus vectors: the effects of chimeric mRNA structure, helper virus, and adenovirus VA1 RNA. Virology (1987) 1.35
An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther (1995) 1.32
Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA. J Natl Cancer Inst (1981) 1.30
The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy (1995) 1.25
Intracellular distribution and polyadenylate content of adeno-associated virus RNA sequences. Virology (1976) 1.23
Parvovirus RNA transcripts containing sequences not present in mature mRNA: a method for isolation of putative mRNA precursor sequences. Proc Natl Acad Sci U S A (1979) 1.23
Vero cells injected with adenovirus type 2 mRNA produce authentic viral polypeptide patterns: early mRNA promotes growth of adenovirus-associated virus. Proc Natl Acad Sci U S A (1980) 1.23
Adeno-associated virus replication. The effect of L-canavanine or a helper virus mutation on accumulation of viral capsids and progeny single-stranded DNA. J Biol Chem (1981) 1.20
Physical map and strand polarity of specific fragments of adenovirus-associated virus DNA produced by endonuclease R-EcoRI. J Virol (1975) 1.18
Metal ion and substrate structure dependence of the processing of tRNA precursors by RNase P and M1 RNA. J Biol Chem (1990) 1.17
Multiple structures of adeno-associated virus DNA: analysis of terminally labeled molecules with endonuclease R-Hae III. J Virol (1976) 1.16
Characterization of the herpes simplex virus type 1 glycoprotein D mRNA and expression of this protein in Xenopus oocytes. Nucleic Acids Res (1983) 1.16
The effect of interferon on de novo infection of Moloney murine leukemia virus. Cell (1977) 1.16
Third-generation oral contraceptives and venous thrombosis. Lancet (1997) 1.16
Molecular structure of adeno-associated virus variant DNA. J Biol Chem (1980) 1.13
Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol (1999) 1.12
Effect of a viral rep gene on transformation of cells by an adeno-associated virus vector. Virology (1988) 1.10
Adeno-associated viruses having nonsense mutations in the capsid genes: growth in mammalian cells containing an inducible amber suppressor. Virology (1991) 1.08
Interaction of wild-type and mutant adeno-associated virus (AAV) Rep proteins on AAV hairpin DNA. J Virol (1996) 1.06
A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther (1998) 1.05
Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells. J Biol Chem (1979) 1.04
Chromatin-like structure of adeno-associated virus DNA in infected cells. J Virol (1983) 1.03
Two stages in the replication of bacteriophage lambda DNA. Biochim Biophys Acta (1969) 1.01
Adeno-associated virus vectors for gene therapy of cystic fibrosis. Methods Enzymol (1998) 1.01
Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology (2001) 0.99
Mitochondrial autonomy. Sialic acid residues on the surface of isolated rat cerebral cortex and liver mitochondria. J Cell Biol (1972) 0.98
Adeno-associated virus DNA structure. Restriction endonuclease maps and arrangement of terminal sequences. Virology (1977) 0.98
Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line. Cancer Res (1986) 0.98
Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet (1996) 0.97
In vitro detection of guinea pig alloantigens by the macrophage-inhibition technique. Transplantation (1969) 0.96
Surviving breast cancer: a problematic work re-entry. Cancer Pract (1994) 0.94
Expression and rescue of a nonselected marker from an integrated AAV vector. Virology (1988) 0.94
Characterization of iron (II).bleomycin-mediated RNA strand scission. Biochemistry (1993) 0.93
Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol (2001) 0.93
The inhibitory effect of interferon on a temperature-sensitive mutant of Moloney murine leukemia virus. Virology (1977) 0.93
Vascular adrenergic neuroeffector function does not decline in aged rats. Circ Res (1985) 0.92
Caffeine in plasma and saliva by a radioimmunoassay procedure. J Pharmacol Exp Ther (1976) 0.92
The "Know Your Body" program: a developmental approach to health education and disease prevention. Prev Med (1980) 0.92
Detection of HSP 72 synthesis after acoustic overstimulation in rat cochlea. Hear Res (1993) 0.92
In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis. Adv Pharmacol (1997) 0.90
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. Br J Clin Pharmacol (1999) 0.89
Presence of growth factors in human pituitary. Lab Invest (1992) 0.89
Chronic disease risk factors among children. The 'Know Your Body' study. J Chronic Dis (1979) 0.88